Rheumatoid arthritis is a chronic autoimmune disease that leads to inflammation of the joints. Various immunosuppressive medications are approved for treatment, but a significant proportion of patients respond inadequately to established therapies. B cells play an important role in rheumatoid arthritis. In our study, we used T-cell engagers for the first time to treat refractory rheumatoid arthritis. T-cell engagers act as a bridge between T cells and B cells, leading to the elimination of B cells. Therapy with the T-cell engager blinatumomab was well tolerated, effectively reduced B cells in the blood and joints, and resulted in a significant reduction in joint inflammation. Thus, T-cell engagers could represent a new treatment option for patients with rheumatoid arthritis and other autoimmune diseases.

Here you can find further information.